Related references
Note: Only part of the references are listed.Intensive home care supports, informal care and private provision for people with dementia in Ireland
Laura Carter et al.
DEMENTIA-INTERNATIONAL JOURNAL OF SOCIAL RESEARCH AND PRACTICE (2021)
Estimating a cost-effectiveness threshold for the Spanish NHS
Laura Vallejo-Torres et al.
HEALTH ECONOMICS (2018)
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System
Laura Catherine Edney et al.
PHARMACOECONOMICS (2018)
Health Care Spending in the United States and Other High-Income Countries
Irene Papanicolas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Spending on Antineoplastic Agents in the United States, 2011 to 2016
Samuel J. Hong et al.
Journal of Oncology Practice (2018)
Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland
Nicola Allen et al.
VALUE IN HEALTH (2017)
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2017)
Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18
Victoria Divino et al.
HEALTH AFFAIRS (2016)
Recent Trends in Prescription Drug Costs
Cynthia Cox et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Pawel Kawalec et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland
Susanne Schmitz et al.
PHARMACOECONOMICS (2016)
The Pharmacoeconomic Evaluation Process in Ireland
Laura McCullagh et al.
PHARMACOECONOMICS (2016)
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Claxton et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Daniel M. Hartung et al.
NEUROLOGY (2015)
Pricing in the Market for Anticancer Drugs
David H. Howard et al.
JOURNAL OF ECONOMIC PERSPECTIVES (2015)
A cceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
Elizabeth A. Griffiths et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2015)
Shining a light in the black box of orphan drug pricing
Eline Picavet et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
High Cancer Drug Prices in the United States: Reasons and Proposed Solutions
Hagop Kantarjian et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Pricing for Orphan Drugs Will the Market Bear What Society Cannot?
Brian P. O'Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Reimbursement Decisions of the All Wales Medicines Strategy Group Influence of Policy and Clinical and Economic Factors
Warren G. Linley et al.
PHARMACOECONOMICS (2012)
Pricing and reimbursement of orphan drugs: the need for more transparency
Steven Simoens
ORPHANET JOURNAL OF RARE DISEASES (2011)
Demythologizing the high costs of pharmaceutical research
Donald W. Light et al.
BIOSOCIETIES (2011)
Share Paper
